ASND רווח נקי למניה ב-12 החודשים האחרונים ascendispharma.com
Ascendis Pharma A/S (ASND) faces a fierce race for speed-to-market for drugs within the rare disease niche. The company is currently transitioning toward product commercialization, which ensures financial autonomy. Success is based on the TransCon method and the academic culture of Danish chemists. The rolling earnings per share trend visualizes these processes, while the 13.08 indicator reflects the current dynamics of per-unit income.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_ASND_-_Ascendis-Pharma-AS_-_Earnings-per-share-for-the-last-four-quarters "Ascendis Pharma Inc. - רווח נקי למניה (EPS TTM) ASND (תקופה 04.07.2022 - 12.11.2026) | 👁️GURU.Markets👁️")
פילוחים אנליטיים ודוחות נתונים של חברת Ascendis Pharma AS (ASND)
Ascendis Pharma A/S (ASND) is strengthening its position in the pharmaceutical market by replacing daily therapies with long-acting injections powered by the TransCon platform. The effectiveness of this strategy is quantified through the ratio of net income to the number of shares over a rolling year, which filters out issuance noise and allows for an assessment of real per-share returns based on the net income per share dynamics over the last 12 months.
